The D2S and D2L dopamine receptor isoforms are differentially regulated in Chinese hamster ovary cells

LJ Zhang, JE Lachowicz and DR Sibley

Molecular Neuropharmacology Section, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland 20892.

To investigate and compare the regulatory properties of the two isoforms of the D2 dopamine receptor, we have stably expressed their cDNAs in Chinese hamster ovary (CHO) cells. Cell lines were selected that express similar levels of [3H]methylspiperone-binding activity. Both isoforms mediate a dose-dependent and pharmacologically specific inhibition of adenylyl cyclase activity in both intact cell and membrane preparations. Pretreatment of both D2L and D2S receptor- expressing cells with 100 microM dopamine produces a approximately 5- fold shift (to lower affinity) in the EC50 for dopamine inhibition of cAMP accumulation, with a 25-30% decrease in the maximum response. Dopamine treatment also results in a approximately 25% decrease in the maximum receptor binding activity of the D2S receptor-expressing cells. In contrast, the D2L receptors are up-regulated by about 2-fold in response to dopamine exposure. This difference in response between the D2S and D2L receptors is not cell line specific, inasmuch as other CHO clones expressing these isoforms show identical responses. The dopamine- induced up-regulation of D2L receptor binding is time dependent, reaching maximal levels after 10 hr (t1/2 = 2 hr). Upon removal of dopamine, the receptor binding activity returns to control levels within 20 hr. The adenylyl cyclase desensitization response is also time dependent but exhibits a slower time course (t1/2 = 5 hr) than the receptor up-regulation. Both regulatory responses are induced in a dose- dependent fashion by dopamine, albeit with different potencies (up- regulation EC50 = 100 nM, desensitization EC50 = 2 microM). These regulatory effects are pharmacologically specific, being mimicked by D2- selective agonists but not agonists of other receptor subtypes. The dopamine-induced receptor up-regulation is blocked by prior treatment of the cells with pertussis toxin and is not mimicked by cAMP analogs. Conversely, elevation of intracellular cAMP levels results in down- regulation of the D2L receptor activity. To test whether protein synthesis is required for the D2L receptor up-regulation, cycloheximide was used to block mRNA translation. This was found to completely inhibit the up-regulation of D2L binding activity; however, there was no effect on the desensitization of the adenylyl cyclase response. RNA dot-blot analyses indicate that dopamine treatment is associated with a sustained 2-fold increase in the steady state levels of D2L mRNA, whereas D2S mRNA is transiently increased by only 50%.(ABSTRACT TRUNCATED AT 400 WORDS)

Volume 45, Issue 5, pp. 878-889, 05/01/1994
Copyright © 1994 by American Society for Pharmacology and Experimental Therapeutics

This article has been cited by other articles:

				P.-A. Vidi, B. R. Chemel, C.-D. Hu, and V. J. Watts Ligand-Dependent Oligomerization of Dopamine D2 and Adenosine A2A Receptors in Living Neuronal Cells Mol. Pharmacol., September 1, 2008; 74(3): 544 - 551. [Abstract] [Full Text] [PDF]

				C. H. So, V. Verma, B. F. O'Dowd, and S. R. George Desensitization of the Dopamine D1 and D2 Receptor Hetero-Oligomer Mediated Calcium Signal by Agonist Occupancy of Either Receptor Mol. Pharmacol., August 1, 2007; 72(2): 450 - 462. [Abstract] [Full Text] [PDF]

				M. F. Lopez-Aranda, M. J. Acevedo, A. Gutierrez, P. Koulen, and Z. U. Khan Role of a G{alpha}i2 protein splice variant in the formation of an intracellular dopamine D2 receptor pool J. Cell Sci., July 1, 2007; 120(13): 2171 - 2178. [Abstract] [Full Text] [PDF]

				C. H. So, G. Varghese, K. J. Curley, M. M. C. Kong, M. Alijaniaram, X. Ji, T. Nguyen, B. F. O'Dowd, and S. R. George D1 and D2 Dopamine Receptors Form Heterooligomers and Cointernalize after Selective Activation of Either Receptor Mol. Pharmacol., September 1, 2005; 68(3): 568 - 578. [Abstract] [Full Text] [PDF]

				L. Thielemans, I. Depoortere, J. Perret, P. Robberecht, Y. Liu, T. Thijs, C. Carreras, E. Burgeon, and T. L. Peeters Desensitization of the Human Motilin Receptor by Motilides J. Pharmacol. Exp. Ther., June 1, 2005; 313(3): 1397 - 1405. [Abstract] [Full Text] [PDF]

				T. A. Macey, V. V. Gurevich, and K. A. Neve Preferential Interaction between the Dopamine D2 Receptor and Arrestin2 in Neostriatal Neurons Mol. Pharmacol., December 1, 2004; 66(6): 1635 - 1642. [Abstract] [Full Text] [PDF]

				Y. Namkung and D. R. Sibley Protein Kinase C Mediates Phosphorylation, Desensitization, and Trafficking of the D2 Dopamine Receptor J. Biol. Chem., November 19, 2004; 279(47): 49533 - 49541. [Abstract] [Full Text] [PDF]

				W. Liang, S. Austin, Q. Hoang, and P. H. Fishman Resistance of the Human {beta}1-Adrenergic Receptor to Agonist-mediated Down-regulation: ROLE OF THE C TERMINUS IN DETERMINING {beta}-SUBTYPE DEGRADATION J. Biol. Chem., October 10, 2003; 278(41): 39773 - 39781. [Abstract] [Full Text] [PDF]

				J. Duan, M. S. Wainwright, J. M. Comeron, N. Saitou, A. R. Sanders, J. Gelernter, and P. V. Gejman Synonymous mutations in the human dopamine receptor D2 (DRD2) affect mRNA stability and synthesis of the receptor Hum. Mol. Genet., February 1, 2003; 12(3): 205 - 216. [Abstract] [Full Text] [PDF]

				P. A. Zaki, D. E. Keith Jr., J. B. Thomas, F. I. Carroll, and C. J. Evans Agonist-, Antagonist-, and Inverse Agonist-Regulated Trafficking of the delta -Opioid Receptor Correlates with, but Does Not Require, G Protein Activation J. Pharmacol. Exp. Ther., September 1, 2001; 298(3): 1015 - 1020. [Abstract] [Full Text]

				N. Hukovic, M. Rocheville, U. Kumar, R. Sasi, S. Khare, and Y. C. Patel Agonist-dependent Up-regulation of Human Somatostatin Receptor Type 1 Requires Molecular Signals in the Cytoplasmic C-tail J. Biol. Chem., August 27, 1999; 274(35): 24550 - 24558. [Abstract] [Full Text] [PDF]

				J. A. Schetz, A. Chu, and D. R. Sibley Zinc Modulates Antagonist Interactions with D2-Like Dopamine Receptors through Distinct Molecular Mechanisms J. Pharmacol. Exp. Ther., May 1, 1999; 289(2): 956 - 964. [Abstract] [Full Text]

				C. MISSALE, S. R. NASH, S. W. ROBINSON, M. JABER, and M. G. CARON Dopamine Receptors: From Structure to Function Physiol Rev, January 1, 1998; 78(1): 189 - 225. [Abstract] [Full Text] [PDF]

				G. Y. K. Ng, G. Varghese, H. T. Chung, J. Trogadis, P. Seeman, B. F. O'Dowd, and S. R. George Resistance of the Dopamine D2L Receptor to Desensitization Accompanies the Up-Regulation of Receptors on to the Surface of Sf9 Cells Endocrinology, October 1, 1997; 138(10): 4199 - 4206. [Abstract] [Full Text] [PDF]

				D. S. Cowen, P. B. Molinoff, and D. R. Manning 5-Hydroxytryptamine1A Receptor-Mediated Increases in Receptor Expression and Activation of Nuclear Factor-kappa B in Transfected Chinese Hamster Ovary Cells Mol. Pharmacol., August 1, 1997; 52(2): 221 - 226. [Abstract] [Full Text]

				M. J. Smit, E. Roovers, H. Timmerman, Y. van de Vrede, A. E. Alewijnse, and R. Leurs Two Distinct Pathways for Histamine H(2) Receptor Down-regulation J. Biol. Chem., March 29, 1996; 271(13): 7574 - 7582. [Abstract] [Full Text] [PDF]

				C. S. Fishburn, Z. Elazar, and S. Fuchs Differential Glycosylation and Intracellular Trafficking for the Long and Short Isoforms of the D(2) Dopamine Receptor J. Biol. Chem., December 15, 1995; 270(50): 29819 - 29824. [Abstract] [Full Text] [PDF]